Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 39.7 kDa. The protein migrates as 45-54 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human TIGIT, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Human TIGIT, Fc Tag (Cat. No. TIT-H5254) is more than 90% and the molecular weight of this protein is around 85-100 kDa verified by SEC-MALS.
Immobilized Human CD155, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. CD5-H5254) at 5 μg/mL (100 μL/well) can bind Human TIGIT, Fc Tag (Cat. No. TIT-H5254) with a linear range of 0.6-10 ng/mL (QC tested).
Serial dilutions of Human TIGIT Neutralizing antibody were added into Human TIGIT, Fc Tag (Cat. No. TIT-H5254): Biotinylated Human CD155, Fc,Avitag (Cat. No. CD5-H82F6) binding reactions. The half maximal inhibitory concentration (IC50) is 0.55834 μg/mL (Routinely tested).
Loaded Human TIGIT, Fc Tag (Cat. No. TIT-H5254) on Protein A Biosensor, can bind Human CD155, His Tag (Cat. No. CD5-H5223) with an affinity constant of 0.98 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
FACS assay shows that recombinant Human TIGIT, Fc Tag (Cat. No. TIT-H5254) can bind to 293T cell overexpressing human CD155. The concentration of TIGIT used is 0.1 μg/mL (Routinely tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides innovative solutions for neuroscience research. Recombinant proteins, neural factors, pre-formed fibrils, electrophysiological electrodes, as well as Organoid Toolbox all in Aneuro aiming to advance neuroscience research, develop therapeutic interventions, and improve diagnostic methods for neurological diseases.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Fecha | Indications | Clinical Trials |
---|
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Vibostolimab | MK-7684 | Phase 3 Clinical | Merck Sharp & Dohme Corp | Solid tumours; Small Cell Lung Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
Domvanalimab | AB-154 | Phase 3 Clinical | Arcus Biosciences Inc, Gilead Sciences Inc | Carcinoma, Adenosquamous; Carcinoma, Hepatocellular; Melanoma; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Lung Neoplasms; Esophageal adenocarcinoma; Cholangiocarcinoma; Biliary Tract Neoplasms; Urinary Bladder Neoplasms; Glioblastoma; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Solid tumours; Liver Neoplasms | Details |
Tiragolumab | RO-7092284; MTIG-7192A; RG-6058 | Phase 3 Clinical | F. Hoffmann-La Roche Ltd | Carcinoma, Squamous Cell; Multiple Myeloma; Chordoma; Lymphoma, Follicular; Breast Neoplasms; Sarcoma; Esophageal Squamous Cell Carcinoma; Lymphoma, Non-Hodgkin; Mouth Neoplasms; Carcinoma, Medullary; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Adenocarcinoma; Hemangioendothelioma, Epithelioid; Neoplasm Metastasis; Stomach Neoplasms; Liver Neoplasms; Teratoma; Lymphoma, B-Cell; Head and Neck Neoplasms; Carcinoma, Renal Cell; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Solid tumours; Esophageal Neoplasms; Rhabdoid Tumor; Carcinoma, Transitional Cell; Glioblastoma; Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms | Details |
Pembrolizumab/Vibostolimab | MK-7684A | Phase 3 Clinical | Merck & Co Inc | Urinary Bladder Neoplasms; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Gallbladder Neoplasms; Endometrial Neoplasms; Lung Neoplasms; Cholangiocarcinoma; Ovarian Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Hematologic Neoplasms | Details |
Rilvegostomig | AZD-2936 | Phase 3 Clinical | Astrazeneca Plc | Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Ociperlimab | BGB-A1217 | Phase 3 Clinical | Beigene Ltd | Solid tumours; Biliary Tract Neoplasms; Lymphoma, B-Cell; Esophageal Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Lymphoma, Large B-Cell, Diffuse; Cholangiocarcinoma; Nasopharyngeal Carcinoma; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms | Details |
Etigilimab | OMP-313M32 | Phase 2 Clinical | Oncomed Pharmaceuticals Inc | Ovarian Neoplasms; Solid tumours; Neoplasms; Adenocarcinoma, Clear Cell; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Neoplasm Metastasis | Details |
Renvistobart | BMS-986207 | Phase 2 Clinical | Bristol-Myers Squibb Company | Solid tumours; Ovarian Neoplasms; Head and Neck Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
ZG-005 | ZG-005 | Phase 2 Clinical | Gensun Biopharma Inc | Solid tumours; Neoplasms; Carcinoma, Neuroendocrine; Uterine Cervical Neoplasms | Details |
HB-0036 | HB-0036 | Phase 2 Clinical | Huabo Biopharm Co Ltd | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
AGEN-1777 | AGEN-1777; BMS-986442 | Phase 2 Clinical | Agenus Inc | Solid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
PM-1022 | PM-1022 | Phase 2 Clinical | Biotheus Inc | Neoplasms | Details |
Lancastotug | AK-127 | Phase 2 Clinical | Zhongshan Akeso Biopharma Co Ltd | Solid tumours; Neoplasms; Carcinoma, Hepatocellular | Details |
Belrestotug | EOS-448; EOS-884448; GSK-4428859; GSK-4428859A | Phase 2 Clinical | Iteos | Head and Neck Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Multiple Myeloma; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
HLX-301 | HLX-301 | Phase 2 Clinical | Shanghai Henlius Biologics Co Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Lymphoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
HLX-53 | HLX-53; HLX53 | Phase 2 Clinical | Shanghai Henlius Biologics Co Ltd | Solid tumours; Neoplasms; Lymphoma; Carcinoma, Hepatocellular; Neoplasm Metastasis | Details |
HL-301 | HL-301 | Phase 2 Clinical | Hanlim Pharm Co Ltd | Radiation Pneumonitis; Small Cell Lung Carcinoma; Lung Neoplasms | Details |
JS-006 | JS-006; TAB-006; CHS-006 | Phase 2 Clinical | Shanghai Junshi Biosciences Co Ltd | Solid tumours; Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
Dargistotug | M-6223; M6223 | Phase 2 Clinical | Emd Serono Research & Development Institute Inc | Solid tumours; Carcinoma, Transitional Cell; Neoplasm Metastasis | Details |
DW-2008 | DW-2008; DW-2008S | Phase 1 Clinical | Dong Wha Pharm Co Ltd | Coronavirus Disease 2019 (COVID-19); Rhinitis, Allergic; Asthma | Details |
Tamgiblimab | IBI-939 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Neoplasms; Lung Neoplasms | Details |
COM-902 | COM-902 | Phase 1 Clinical | Compugen Ltd | Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Small Cell Lung Carcinoma; Neoplasms; Colonic Neoplasms; Multiple Myeloma; Neoplasms, Plasma Cell; Colorectal Neoplasms; Lung Neoplasms | Details |
AK-130 | AK-130 | Phase 1 Clinical | Zhongshan Akeso Biopharma Co Ltd | Neoplasms; Carcinoma, Hepatocellular | Details |
SIM-0348 | SIM-0348 | Phase 1 Clinical | Simcere Pharmaceutical Group Ltd | Solid tumours; Neoplasms | Details |
Recombinant humanized anti-TIGIT monoclonal antibody(Lepu biopharma) | LP-010 | Phase 1 Clinical | Lepu Biotech Co Ltd | Solid tumours | Details |
ASP-8374 | ASP-8374; PTZ-201 | Phase 1 Clinical | Potenza Therapeutics, Astellas Pharma Inc | Solid tumours; Glioblastoma | Details |
ZGGS-15 | ZGGS15; ZGGS-15 | Phase 1 Clinical | Suzhou Zelgen Biopharmaceuticals Co Ltd | Solid tumours | Details |
AUR-106 | AUR-106 | Phase 1 Clinical | Aurigene Discovery Technologies Ltd | Kidney Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Colonic Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
BC008-1A | BC008-1A | Phase 1 Clinical | Sichuan Luzhou Buchang Biopharmaceutical Co Ltd | Solid tumours | Details |
SHR-2002 | SHR-2002 | Phase 1 Clinical | Suzhou Suncadia Biopharmaceuticals Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd | Neoplasms | Details |
PM-1021 | PM1021 | Phase 1 Clinical | Biotheus Inc | Solid tumours; Neoplasms | Details |
SHS-006(Nanjing Sanhome Pharmaceutical) | SHS-006; SH-006; SH006 | Phase 1 Clinical | Nanjing Sanhome Pharmaceutical Co Ltd | Solid tumours | Details |
HB0030 | HB-0030 | Phase 1 Clinical | Huabo Biopharm Co Ltd, Shanghai Huaota Biopharmaceutical Co Ltd | Solid tumours | Details |
BAT-6005 | BAT-6005 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours | Details |
IBI-321 | IBI-321 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Neoplasms | Details |
Ralzapastotug | AB-308 | Phase 1 Clinical | Arcus Biosciences Inc | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Adenocarcinoma | Details |
PM-1009 | PM1009 | Phase 1 Clinical | Biotheus Inc | Solid tumours; Neoplasms; Lung Neoplasms | Details |
This web search service is supported by Google Inc.